Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of AT2101 (afegostat tartrate) in adults with type 1 Gaucher disease
2008-007158-36Phase 2Terminated
- Sponsor
- Amicus Therapeutics
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Afegostat in Gaucher disease type 1 (GD1), sponsored by Amicus Therapeutics. Primary endpoint: Safety examinations. Started Apr 2009; status: terminated.
02
Drugs
Afegostat
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on 2008-007158-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007158-36.